Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.27 USD
-0.01 (-0.30%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABUS 3.27 -0.01(-0.30%)
Will ABUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABUS
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
ABUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know
Other News for ABUS
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board ...
Arbutus Biopharma (ABUS) Reacquires China Rights to Lead Drug | ABUS Stock News
Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB
Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB